AQST

Aquestive Therapeutics, Inc.

$3.52

-0.56%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.

Source: Yahoo Finance
AI summary

Price & performance

1M-16.5%
3M+1.6%
YTD-41.1%
1Y-37.5%
52-week range—
Beta1.35
Full chart and returns against a benchmark

Q-Score

43/ 100

Quality against peers; 50 is the peer median.

Growth48
Risk51
Performance62
Valuation37
Profitability28
Leverage41
Sentiment56
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$44.5M-22.6%
Net income-$83.8M
Net margin-188.1%-111.4 pts
Historical fundamentals

Revenue exposure

34%of revenue from outside the US
United States66%
Non-US34%
Largest customer73%
Regions, segments, customers and suppliers

Valuation

AQSTIndustryP/E—35.25P/S9.062.74EV/EBITDA—16.35P/B—2.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 3next report
EPS estimate$-0.14
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate